An orphan receptor discovered in 1993 was called bombesin receptor subtype 3 (BRS-3) because of 47-51% amino acid identity with bombesin (Bn) receptors. Its pharmacology is unknown, because no naturally occurring tissues have sufficient receptors to allow studies. ]Bn-(6 -14) bound to both cell lines with high affinity. Neither Bn nor 14 other naturally occurring Bn peptides bound to hBRS-3 with a K d <1000 nM. Twenty-six synthetic peptides that are high affinity agonists or antagonists at other bombesin receptors had an affinity >1000 nM. Guanosine 5-(␤,␥-imido)triphosphate inhibited binding to both cells due to a change in receptor affinity. These results demonstrate hBRS-3 has a unique pharmacology. It does not interact with high affinity with any known natural agonist or high affinity antagonist of the Bn receptor family, suggesting the natural ligand is either an undiscovered member of the Bn peptide family or an unrelated peptide. The availability of these cell lines and the hBRS-3 ligand should facilitate identification of the natural ligand for BRS-3, its pharmacology, and cell biology.
Recently, an orphan receptor that is a member of the heptahelical superfamily of receptors was described in both human small cell lung cancer cells (1) and guinea pig uterus (2) . Because this orphan receptor had a high degree of homology to mammalian bombesin receptors (i.e. 51-52% for the gastrinreleasing peptide receptor (GRP-R) 1 and 47% for the neuromedin B receptor (NMB-R) (1, 2)), it was named the BRS-3 for bombesin receptor subtype-3 in one study (1) . Studies of the distribution of the receptor mRNA show that BRS-3 has a pattern of expression limited to rat secondary spermatocytes (1) , guinea pig brain and pregnant uterus (2) , and some tumor cell lines (various human small cell and non-small cell lung cancer cell lines (1), the human ductal breast cancer cell line T47D (3) , and the human epidermal cancer cell line A431 (3)). However, the natural ligand that interacts with the BRS-3 is unknown, and its pharmacology is largely unknown because of the lack of a radioligand. In addition, little is known about the cellular basis of action of BRS-3 except that it is coupled to phospholipase C when expressed in Xenopus oocytes (1) or when transfected into Balb 3T3 cells (4) . The ability to elucidate the pharmacology of the BRS-3 is not only limited by the lack of a radioligand but also by the lack of a cell containing native BRS-3 receptors in sufficient numbers to allow binding studies to identify a possible radioligand.
To deal with this latter issue, in the present study we have used two different strategies to produce cell lines stably expressing the human BRS-3 (hBRS-3) receptor whose pharmacology and coupling will probably closely resemble that of the native hBRS-3. Furthermore, we have discovered a unique ligand that is a synthetic analogue of bombesin- (6 -14) , which interacts with high affinity with the hBRS-3. With this radioligand, we demonstrate for the first time that the hBRS-3 possesses a unique pharmacology for mammalian bombesin receptors, that BRS-3 is G protein-coupled, and that none of the existing natural occurring bombesin-related peptides are the natural ligand for this receptor.
chloro-3␣-6␣-diphenylglycouril (Iodo-Gen) was from Pierce; bombesin (Bn), gastrin-releasing peptide (GRP), neuromedin B (NMB), litorin, ranatensin, alytesin, neuromedin C (NMC), phyllolitorin, [Tyr 4 ]Bn, and rohdei-litorin were from Bachem (Torrence, 
Methods
Preparation of Peptides-The peptides were synthesized with solidphase methods as described previously (5) (6) (7) . Briefly, introduction of the reduced peptide bond was carried out by the standard methods described previously (5, 7) on methylbenzhydrylamine resin (Advanced Chem Tech, Louisville, KY). Alkylamide analogues were synthesized in a standard Leu-O-polystyrene resin by using tosyl group protection for the imidazole group of His. Peptide esters were prepared by standard, automated solid-phase techniques on Advanced Chem Tech ACT200 machines with Merrifield Leu-O-polystyrene resin and ␣-Boc protection for all amino acids and both the ␣ and imidazole nitrogen of His in position 12 as described previously (6) . Free peptides were then cleaved from the resin by transesterification with 10% triethylamine/methanol at 40°C (2 days). Peptides were purified as described previously (5-7) to greater than 97% purity. Peptides were characterized by amino acid analysis and matrix-assisted laser desorption mass spectroscopy (Finnegan, Hemel Hemstead, UK).
Growth and Maintenance of Cells-Balb 3T3 and hBRS-3-transfected Balb 3T3 cells were grown in Dulbecco's minimum essential medium. NCI-H1299 and hBRS-3-transfected H1299 cells were grown in RPMI 1640. Both cell media were supplemented with 10% (v/v) fetal bovine serum (Life Technologies), penicillin (50 units/ml), and streptomycin (50 g/ml) (Life Technologies) (plus 300 g/ml G418 sulfate for stable transfectants). All cells were maintained at 37°C in a 5% CO 2 atmosphere. Cells were passaged every 3-4 days at confluence after detaching the cells with 0.1% trypsin in 1 mM EDTA.
Isolation of Cellular RNA and Northern Blot-Cells were harvested in GIT buffer (4 M guanidine isothiocyanate, 30 mM sodium acetate, pH 7.0, and 1% (v/v) 2-mercaptoethanol), and total cellular RNA was isolated according to the method described by Davis et al. (8) . Fifteen-g samples were subjected to denaturing gel electrophoresis in formaldehyde agarose (0.22 M and 1% (w/v), respectively) and then transferred to nitrocellulose (Schleicher & Schuell, Keene, NH) according to the method by Thomas (9) . Total cellular RNA from some cell lines was isolated using the RNeasy Midi kit (QIAGEN Inc., Chatsworth, CA).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Southern blot-For RT-PCR, first strand cDNA was synthesized using 1.0 g of total cellular RNA with the first strand cDNA synthesis kit (Life Technologies). For amplification from first strand cDNAs, genespecific primers for the hBRS-3 were used as described elsewhere (1) . Nested PCR of the hBRS-3 was performed with the following primers: 5Ј-CAGAATCATCAAGCTCTGTG-3Ј (sense) and 5Ј-AGTCTTCAGGAT-GGCATTGG-3Ј (antisense). Gene-specific primers for the hGRP-R were as reported in Pansky et al. (10) . The human NMB-R primers were as follows: 5Ј-CGGACTCTGCTGGAAAGGA-3Ј (sense) and 5Ј-GACGTCT-GCATGTCCATGG-3Ј (antisense). PCR was carried out with the GeneAmp PCR System 9600 (Perkin-Elmer) using routine conditions and buffer provided by the manufacturer. PCR products were electrophoretically separated in 1.2% (w/v) SeaKem GTG agarose gels (FMC BioProducts, Rockland, ME) and transferred to nitrocellulose. Hybridization was carried out at 37°C (Random Primers DNA labeling system probes (Life Technologies)) or at room temperature (end-labeled synthetic oligonucleotides) in a buffer containing 40% (v/v) formamide (Fluka Chemical, Switzerland), 4 ϫ SSC (300 mM NaCl, 30 mM sodium citrate; Research Genetics, Huntsville, AL), 20 mM Tris, pH 7.5 (Quality Biological, Gaithersburg, MD), 10% (v/v) dextran sulfate (Oncor, Gaithersburg, MD), 1 ϫ Denhardt solution (Digene Diagnostics, Beltsville, MD), and 20 g/ml sonicated herring sperm DNA (Digene Diagnostics, Beltsville, MD). Nitrocellulose filters of Northern transfers were hybridized overnight with the full-length human GRP-R, hBRS-3, or human NMB-R (1, 11) cDNA, respectively, and radioactively labeled to a specific activity of about 1 ϫ 10 9 cpm/g DNA. Filters were washed with sequentially increasing stringency, ending with a final wash in 0.1 ϫ SSC, 0.1% SDS (v/v) at 55°C, air-dried, and exposed to x-ray films (XAR, Eastman Kodak Co.). Nitrocellulose filters from Southern transfers were hybridized at room temperature with 32 P-end-labeled, genespecific synthetic oligonucleotides, washed at room temperature as described for Northern transfers, air-dried, and exposed to x-ray films for several hours. Reverse transcription was performed using total cellular RNA. PCR was performed using gene-specific primers for human BRS-3, GRP receptors, or NMB receptor as described under "Methods." Hybridization was performed using 32 P-radiolabeled gene-specific probes as described under "Methods." The top panel shows the results with an hBRS-3-specific probe; the middle panel shows results using an hGRP receptor-specific probe; and the bottom panel shows results with an hNMB receptor probe.
Plasmids-The hBRS-3 cDNA was amplified by PCR from the original cDNA clone (1) generating a 1.3-kilobase pair fragment that included the coding region and an additional 62 base pairs of the immediate 3Ј-untranslated region. A sequence encoding the flag epitope tag (5Ј-GACTACAAGGACGACGATGACAAG-3Ј) was inserted between the first (Met) and second (Ala) amino acid residue of the coding region during PCR extension from the original clone. The epitope-tagged BRS-3 cDNA was cloned into the EcoRI site of the mammalian expression vectors pcDNA3 (Invitrogen; San Diego, CA) and modified pCD2, respectively. The correct DNA sequence of the inserts in the expression plasmids was verified by automatic sequencing on both strands (model A373, Applied Biosystems, Perkin-Elmer).
Stable Transfection-Fifteen g of plasmid DNA (human epitopetagged BRS-3 cDNA in the mammalian expression vectors pCD2 and pcDNA3 (Invitrogen; San Diego, CA)) was used for transfection of NCI-H1299 cells with 25 l of lipofectAMINE (Life Technologies). Balb 3T3 cells were transfected using the CaPO 4 precipitation method as described by Davis et al. (8) . Three days after transfection, cells were split in a ratio of 1:3, and the selection antibiotic G418 (Life Technologies) was added to the regular growth medium at a concentration of 800 g/ml. Single colonies were isolated 2 weeks later and expanded in growth medium containing G418 (300 g/ml). ]Bn- (6 -14) ) were determined at each temperature using centrifugation as described under "Methods." Results are the mean Ϯ S.E. from three experiments, and each point was determined in duplicate. The results are the mean Ϯ S.E. from three experiments, and each point was determined in duplicate. 
a Significantly greater (p Ͻ 0.05) than binding with no cells added. b Significantly greater (p Ͻ 0.01) than nontransfected cells.
bacitracin. 1 ϫ 10 7 cells/ml were homogenized at 4°C with a polytron (Brinkman Instruments) at the speed of 6 for 30 s. The homogenized suspension was centrifuged at 1500 rpm for 10 min at 4°C. The supernatant was removed and recentrifuged at 20,000 rpm for 20 min. The pellet was resuspended in homogenizing buffer and stored at Ϫ20°C. (13) did not undergo the incubation with dithiothreitol. Radiolabeled peptides were separated using a Sep-Pak and high pressure liquid chromatography as described previously (12, 13) . Radioligands were stored with 0.5% bovine serum albumin at Ϫ20°C.
Binding of 125 I-Labeled Peptides to Transfected and Untransfected Cells-
The standard binding buffer contained 24.5 mM HEPES (pH 7.4), 98 mM NaCl, 6 mM KCl, 2.5 mM NaH 2 PO 4 , 5 mM sodium pyruvate, 5 mM sodium fumarate, 5 mM sodium glutamate, 2 mM glutamine, 11.5 mM glucose, 0.5 mM CaCl 2 , 1.0 M MgCl 2 , 0.01% soybean trypsin inhibitor, 0.2% (v/v) amino acid mixture, 0.2% bovine serum albumin, and 0.1% bacitracin. Incubations contained 50 pM 125 I-labeled ligand and 1-2 ϫ 10 6 cells/ml (unless otherwise stated) and were for the indicated durations at the indicated temperatures. (6 -14) and 200 g of cell membrane protein in a 300-l incubation volume with or without unlabeled ligands. The nonsaturable binding of radiolabeled ligand was the amount of radioactivity associated with the cell membranes in incubations containing 50 pM ligand plus 1 M of unlabeled ligand and was Ͻ15% of the total binding. Incubations were performed at 22°C for 45 min. non-small cell lung cancer cell line, NCI-H1299, which we planned to use to make stable cell lines containing BRS-3, we initially used Northern blot analysis ( Fig. 1) and did not detect hBRS-3 mRNA in either cell line; nor was the hGRP receptor or hNMB receptor mRNA detected (Fig. 1) . In contrast, employing RT-PCR and Southern blot analysis, the BRS-3 receptor was present in native H1299 cells but not in native Balb 3T3 cells (Fig. 2, top panel, lanes 1 and 2) . Similarly, the hGRP receptor (Fig. 2, middle panel, lanes 1 and 2) and hNMB receptor (Fig.  2, bottom ]Bn-(6 -13)methyl ester (13)) showed low levels of GRP receptors (Table I) . In contrast, native Balb 3T3 cells did not demonstrate significant saturable binding with any of the four NMB-R or GRP-R ligands (Table I) .
RESULTS

Preparation of hBRS-3-transfected Cells-Two
H1299 and Balb 3T3 cells stably expressing the hBRS-3 were identified by Northern blot analysis (Fig. 1) . The results from five clones stably expressing hBRS-3 in NCI-H1299 cells (H1299 clones 4, 5, 12, 25, and 26 ) and three clones in Balb 3T3 cells (Balb hBRS-3 clones 10, 11, and 14) are shown in Fig. 1 (Table I) Table I . One NCI-H1299 clone (number 5) and one hBRS-3-transfected Balb 3T3 clone (number 10) demonstrating high binding were used to characterize hBRS-3 pharmacology in the following studies.
Binding of [ 125 I-D-Tyr 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) to either hBRS-3-transfected H1299 cells (clone 5) (Fig. 3) or hBRS-3-transfected Balb 3T3 cells (data not shown) was time-and temperature-dependent. Binding was rapid at 22°C or 37°C, reaching maximal by 20 min and then was constant for 40 min (Fig. 3) . Binding at either temperature was reduced Ͼ85% by the addition of unlabeled [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) (Fig. 3) . Decreasing the temperature to 4°C slowed the rate of binding such that by 60 min only 50% of the maximal binding seen at 22 or 37°C was seen (Fig. 3) .
Binding of [ 125 I-D-Tyr 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) to both cell lines was reversible, and the dissociation rate was temperature-dependent. In hBRS-3-transfected H1299 cells (clone 5) (Fig. 4) or hBRS-3-transfected Balb 3T3 cells (clone 10) (data not shown), 37% of the ligand rapidly dissociated within the first 2 min, and an additional 30% slowly dissociated over an additional 40 min at 37°C. The dissociation rate was markedly slowed at 4°C such that after a 45-min incubation only 25% dissociated at 4°C (Fig. 4) .
To assess ligand stability, hBRS-3-transfected H1299 cells (Fig. 3) , and the supernatants were analyzed using high pressure liquid chromatography. 14 ]Bn-(6 -14) in a dose-dependent manner in both hBRS-3-transfected H1299 cells (Fig. 5, top) or hBRS-3-transfected Balb 3T3 cells (Fig. 5, bottom) (Table II) or H1299 cells (data not shown), the ability of various peptides or neurotransmitters that interact with receptors different from the bombesin receptor family was tested (Table II) (Table II) or hBRS-3 H1299-transfected cells (data not shown).
To assess the affinity of the hBRS-3 receptor for known, naturally occurring Bn-related peptides, the affinities for bombesin, GRP, NMB (Fig. 6) , and 12 other natural occurring members of the bombesin family of peptides (Table III) were determined in hBRS-3-transfected H1299 cells (Fig. 6, top ;  Table III ) and Balb 3T3 cells (Fig. 6, bottom; Table II ). Both cell lines had almost no affinity for bombesin or GRP (Ͼ10,000 nM) (Fig. 6 , Table III ). NMB had a 300 -400-fold lower affinity in both hBRS-3-transfected cell lines than [D-Tyr 6 ,␤-Ala
11
,Phe 13 , Nle 14 ]Bn-(6 -14) (Fig. 6 , Table III ). Each of the 12 other natural occurring bombesin-related peptides (4, 18 -20) had low affinity (Ͼ2 M) for the hBRS-3 receptors in each of the hBRS-3-transfected cell lines (Table III) . These results differed markedly from the ability of these natural occurring bombesin-related peptides to interact with the GRP receptor in rat pancreatic acini or the NMB receptor in rNMB-transfected Balb 3T3 cells (Table III) . Specifically, six of these peptides ([Phe 13 ]Bn (4), NMC, PG-L (18), litorin, ranatensin, bombesin) had high affinity (Ͻ5 nM) for the GRP receptor (Table II) , and two had high affinity (Ͻ10 nM) for the NMB receptor (NMB, litorin).
Five different classes of GRP receptor antagonists have been described, and two classes of NMB receptor antagonists (21-24) have been described. Twenty-two members of each of these classes of GRP receptor or NMB receptor antagonists (Fig. 7) or closely related synthetic peptides (Table IV) were tested for the ability to interact with the hBRS-3 receptors in each of the transfected cell lines, which was compared with their ability to interact with the native GRP receptor in rat pancreatic acini and the NMB receptor in rNMB-R-transfected Balb 3T3 cells. Each of the 22 bombesin receptor antagonists had low affinity (Ͼ1 M) for the hBRS-3 receptors on each of the two different transfected cell types (Table III) Table IV ) class of GRP receptor and NMB receptor antagonists (23, 25, 26) , three members of the bombesin pseudopeptide class of GRP receptor antagonists (clones 4 -6, Table IV) (7, 27, 28) , two members of the D-Pro 13 pseudopeptide class of potent GRP receptor antagonists (clones 7 and 8, Table IV), 11 members of the des-Met 13 classes of amides, esters, alkylamides, and hydrazides (clones 9 -18, Table IV) (which function as selective GRP receptor antagonists . Increasing concentrations of unlabeled peptide were added, and dose-response curves were analyzed using a least-squares, curve-fitting program (LIGAND). K i values were calculated using the method of Cheng and Prusoff (15) . Values are mean Ϯ S.E. from at least four experiments. Ͼ10,000 means the affinity was greater than 10,000 nM. (6, 29 -31)), and one member (clone 20, Table IV ) of the D-amino acid-substituted octapeptide analogues of somatostatin (which function as NMB receptor antagonists (22)). The D-amino acidsubstituted analogues of substance P, or the substance P-(4 -11) class of antagonists (which function as receptor antagonists for GRP receptor, NMB receptor, and other receptors (21, 32-34)), had similar low affinities for the hBRS-3 receptor as those reported for the GRP receptor or the NMB receptor (Fig. 7 , Table IV ) also had low affinity for the hBRS-3 on each transfected cell line (Table IV) .
To determine whether hBRS-3 was coupled to G proteins, the ability of the nonhydrolyzable guanine nucleotide analogue Gpp(NH)p to alter binding of [ 125 I-D-Tyr 6 ,␤-Leu 11 ,Phe 13 ,Nle 14 ] Bn- (6 -14) to each of the hBRS-3-transfected cell lines was examined (Fig. 8) . Gpp(NH)p caused a dose-dependent 70% decrease in binding in hBRS-3-transfected H1299 cell membranes (Fig. 8, top) and a 45% decrease in hBRS-3-transfected Balb 3T3 cell membranes (Fig. 8, bottom) . Gpp(NH)p caused a detectable decrease with 30 nM Gpp(NH)p, a half-maximal effect at 0.25-0.3 M, and a maximal effect at 100 M (Fig. 8) . 
DISCUSSION
In the present study, we describe for the first time a comprehensive analysis of the pharmacology of the orphan receptor, BRS-3, using a newly discovered novel ligand with high affinity for this receptor. To achieve this it was first necessary to prepare stable cell lines expressing the hBRS-3 that would be similar in their receptor pharmacology to the native hBRS-3 receptor. This was necessary because, although previous studies have shown the hBRS-3 to exist on certain tumor cell lines (1) such as various human small cell and non-small cell line cancer cells (1), the human ductal breast cancer cell line T47D (3), and the human epidermal cancer cell line A431 (3), their receptor number was too low to allow ligand studies of direct interaction with the hBRS-3. Therefore, two strategies were used to produce stable cell lines that would resemble native cells possessing this receptor. A stable hBRS-3 cell line in Balb 3T3 cells was made, because in previous studies (12, 14, 35, 36) we had demonstrated Balb 3T3 fibroblasts do not possess receptors for the bombesin receptor family (GRP-R, NMB-R, BRS-3) (12, 14, 35, 36) . However, these cells closely resemble Swiss 3T3 cells, which possess murine GRP-R and have been extensively used to study the GRP and NMB receptors (36, 37) . Specifically, when the mouse GRP receptor (36) , human NMB receptor (35) , human GRP receptor (35) , or rat NMB receptor (14) was expressed in Balb 3T3 cells, all four mammalian bombesin receptors behaved in a fashion indistinguishable from native cells expressing these receptors in interacting with ligands, in G protein coupling, and in their affinity for agonists and antagonists. The second strategy we used was to overex- Table IV .
BRS-3 Receptor Pharmacology
press the hBRS-3 in the human non-small cell lung cancer cell line, NCI-H1299, which has been reported to express a low level of GRP-R, hNMB receptor, and hBRS-3 mRNA (1, 11), a conclusion we confirmed in the present study.
From ligand studies of these two different hBRS-3-containing cell lines produced by these two different strategies, a number of results support the conclusion that we are assessing interaction with the hBRS-3 and that it probably represents the true pharmacology of this receptor. First, the novel hBRS-3 ligand, [ ]Bn-(6 -13)methyl ester (13), was seen demonstrating the specific acquisition of only the hBRS-3 receptor. Second, nontransfected NCI-H1299 nonsmall cell lung cancer cells bound very low levels of this ligand as well as two GRP receptor ligands, which was consistent with the low level of expression of native hBRS-3 and hGRP receptors and mRNA found in this cell line in the present study and reported in a previous study (11) . Similar to the results with the Balb 3T3 cells, after transfection of NCI-H1299 cells with hBRS-3 there was only increased binding of the novel hBRS-3 ligand and no increased binding of ligands that specifically interacted with NMB receptors or GRP receptors. Third, the novel hBRS-3 ligand interaction with the hBRS-3 receptors on each transfected cell line was characteristic of receptor interaction in that it was high affinity, saturable, time-and temperature-dependent, and reversible (41) . Fourth, the novel hBRS-3 ligand binding was specific for the hBRS-3 receptor on each of these stable cell lines because unrelated peptides had no effect on the binding of this ligand. Fifth, both hBRS-3-transfected cell lines acquired high affinity (4 -8 nM) for the novel hBRS-3 ligand but not for any of the 15 natural occurring bombesin-related agonists or 19 synthetic peptides that are known to function as GRP receptor or NMB receptor agonists or antagonists. This finding excludes the possibility the ligand was interacting with a GRP or NMB receptor. That the pharmacology observed probably represents the true pharmacology of the hBRS-3 receptor is supported by the observation that both cell lines demonstrated similar pharmacology.
Our results demonstrate that the hBRS-3 has a unique pharmacologic profile for a member of the bombesin receptor family. Its pharmacology differs in a number of ways from that for either the GRP receptor or NMB receptor. First, some peptides such as litorin, ranatensin, and bombesin have a high affinity for all other Bn receptors. However, each of these three peptides has a low affinity (Ͼ1 M) for the hBRS-3. Second, a number of Bn-related peptides have selective high affinity for either the GRP receptor (GRP, NMC, PG-L, [Phe 13 ]bombesin) or the NMB receptor (NMB), and none of these peptides had high affinity for the hBRS-3. Third, a number of Bn peptides have relatively low affinities for both the NMB receptor and GRP receptor ([Leu 8 ]phyllolitorin, phylolitorin, rohdei-litorin), raising the possibility they could interact with a significantly different subtype of bombesin receptor. However, each of these peptides was also found to have low affinities in the micromolar range for the hBRS-3. Fourth, six different classes of GRP receptor (21, 24) or NMB receptor (22) antagonists have been described, some of which are highly selective. Representative members of each of these different classes of antagonists were examined, and none were found to interact with the hBRS-3 with affinity above the micromolar range.
Our results have some similarities and differences from the three previous studies that have provided some information on the pharmacology of the hBRS-3 receptor (1, 2, 4). Our finding that the hBRS-3 receptor has a low affinity for NMB, GRP, Bn, [Phe 8 ]phyllolitorin, and ranatensin is consistent with the findings that when the hBRS-3 was expressed in Xenopus oocytes, 100-fold higher concentrations of NMB, GRP and bombesin were needed to activate the hBRS-3 than to activate the GRP or the NMB receptor expressed in the same system (1). Furthermore, [Phe 8 ]phyllolitorin or ranatensin even at very high concentrations (10 M) did not activate the hBRS-3 expressed in Xenopus oocytes (1) . Similarly, when the guinea pig BRS-3 receptor was expressed in LLK-PK 1 cells, it had a low affinity for GRP, NMC, and NMB in a binding assay using 125 I-bombesin (2). Our results are consistent with some findings in a recent study (4) examining the effects of various naturally occurring bombesin-related peptides that cause changes in [Ca 2ϩ ] i in Balb 3T3 cells transfected with the hBRS-3. This study concluded that hBRS-3 probably had a higher affinity for the NMB, litorin, and ranatensin than GRP or bombesin. Our results demonstrate that although each of these peptides has a low affinity for the hBRS-3, NMB, ranatensin, and litorin will interact with the BRS-3 in the micromolar range; however, even with concentrations as high as 10 M bombesin, GRP, or NMC have no affinity for this receptor. Our results differ from this latter study (4) in that the synthetic analogue [D-Phe 6 ]Bn-(6 -13) propylamide was reported to have a relatively high affinity (EC 50 Ϫ84 nM) for stimulating changes in [Ca 2ϩ ] i in hBRS-3-transfected Balb 3T3 cells (4); however, we found this analogue to have a low affinity. At present, the explanation for the differences from the study on [Ca 2ϩ ] i (4) is unclear. The differences are not due to inactivity of the peptide in our study, because it had a high affinity for the GRP-R, as reported previously (13, 29) . It remains possible that, in contrast to the GRP-R and NMB-R, there could be large receptor spareness in hBRS-3 receptors such that minimal changes in receptor occupation cause marked changes in [Ca 2ϩ ] i , and therefore the biologic activity dose-response curve for agonist-induced changes in [Ca 2ϩ ] i is far to the left of the receptor occupation curve.
Detailed structure-function studies of the unique ligand [Tyr
